Heron Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Heron Therapeutics, Inc.
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.
Keeping Track: Keytruda Adds TNBC Claim; Finerenone, Brincidofovir, HTX-011 Submitted; CRL For Supernus’ ADHD Drug
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Plus: Valneva confirms supply deal with the UK government for its inactivated vaccine candidate; Humanigen expands manufacturing ahead of Phase III data.
The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.
- Controlled Release
- Drug Delivery
- Other Names / Subsidiaries
- A.P. Pharma, Inc., Heron Therapeutics B.V.